PDF icon PDF herunterladen
Exp Clin Endocrinol Diabetes 1990; 95(1): 77-82
DOI: 10.1055/s-0029-1210937
Original

© J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart · New York

Autoimmune Reactions in a Patient with Malignant Insulinoma Treated by Multiple Low Dose Streptozotocin*)

B. Schulz, B. Hehmke, E. Zander, B. Ziegler
  • Central Institute of Diabetes “Gerhardt Katsch” (Director: OMR Prof. Dr. sc. med. H. Bibergeil), Karlsburg/GDR
*) Dedicated to Professor Dr. H. Bibergeil on the occasion of his 65th birthday
Weitere Informationen

Publikationsverlauf

1989

Publikationsdatum:
16. Juli 2009 (online)

Auch verfügbar aufeRef
 als PDF herunterladen  Lizenzen und Reprints
Preview

Summary

A 66-year-old female patient with a malignant insulinoma was treated with streptozotocin (STZ; Zanosar) in 5 cycles every 4 weeks as 5 day courses with an intravenous dosage of 850 mg per day.

Under this treatment hypoglycemic episodes decreased continously in number as well as severity and — after a delay of 12 months after the last treatment — an overt diabetes mellitus appeared. Plasma insulin concentrations dropped immediately after starting of STZ therapy. On the other hand, islet cell surface antibodies and their complement-dependent cytotoxicity increased continously, being at their highest 6 months after termination of STZ treatment. Thus, STZ is able to induce a specific immune response against islet cells with a progressive damage of malignant insulin producing cells.

Key words

Malignant insulinoma - Streptozotocin - Insulin secretion - Islet cell antibodies - Cytotoxicity